Background
Substantial inter- and intra-individual HIV diversity remains a major challenge in developing successful immune-based therapies. Despite the ability of broadly neutralizing antibodies (bNAbs) to neutralize genetically diverse strains, viral escape mutations can still emerge in vivo. To overcome this, it is essential to gain a deeper understanding of the in vivo evolution of HIV when subject to the pressure imposed by each bNAb. This project aims to identify in vivo escape residues responsible for VRC01 bNAb family resistance, and to inform rational bNAb combinations by evaluating how escape mutations impact sensitivity to other bNAbs.
Methods
We analyzed samples from clinical trial VRC 607/A5378 (NCT02840474) where viremic participants were administered a single dose of either VRC01LS or VRC07-523LS. We sequenced and cloned env genes isolated before and after bNAb infusion and used these to generate pseudoviruses that were tested for bNAb susceptibility. Simultaneously we analyzed PacBio-derived env sequences before and after infusion to identify putative resistance mutations. We quantified env amino acid frequency changes at each position pre- and post- bNAb infusion and integrated this data with a dN/dS analysis to rank each residue by likelihood of conferring escape. Top ranked residue changes were then inserted into a sensitive pre-Env using site-directed mutagenesis and tested for susceptibility to the infused antibody. Confirmed escape mutations were tested against a larger panel of CD4bs bNAbs to measure shared resistance.
Results
Combining pre- and post-infusion residue frequency changes and dN/dS analyses successfully predicted resistance mutations in several participants. In three participants, escape emerged through distinct mutations at residue 279, both in response to VRC01LS and VRC07-523LS. A fourth participant developed resistance to VRC07-523LS through a N280D N460S double mutation. Despite escape emerging in conserved regions of the CD4bs, several CD4bs bNAbs (1-18, N49-P9.6, and N6) potently neutralized the escape variants.
Conclusions
This study presents one of the first in-human mappings of escape from VRC07-523LS and has identified common resistance mutations that can inform sensitivity screening strategies. While viral escape can still occur from this highly broad bNAb, several CD4bs bNAbs are not impacted by the resistance mutations. These findings highlight the potential of combining CD4bs bNAbs to impose stronger constraints on viral escape.